MCID: NCT008
MIFTS: 49

Nicotine Dependence, Protection Against malady

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Nicotine Dependence, Protection Against

Aliases & Descriptions for Nicotine Dependence, Protection Against:

Name: Nicotine Dependence, Protection Against 54
Nicotine Dependence 54 12 29 14 69
Tobacco Use Disorder 12 29 42
Nicotine Addiction, Protection from 54 13
Tobacco Addiction, Susceptibility to 29
Nicotine Addiction 54
Smoking Habit 52

Classifications:



External Ids:

OMIM 54 188890
Disease Ontology 12 DOID:0050742
MeSH 42 D014029
NCIt 47 C54203
SNOMED-CT 64 56294008
UMLS 69 C0028043

Summaries for Nicotine Dependence, Protection Against

MalaCards based summary : Nicotine Dependence, Protection Against, also known as nicotine dependence, is related to schizophrenia and personality disorder. An important gene associated with Nicotine Dependence, Protection Against is GABBR2 (Gamma-Aminobutyric Acid Type B Receptor Subunit 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Nanog in Mammalian ESC Pluripotency. The drugs Acetylcysteine and Bupropion have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and homeostasis/metabolism

Description from OMIM: 188890

Related Diseases for Nicotine Dependence, Protection Against

Diseases related to Nicotine Dependence, Protection Against via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 30.0 ANKK1 CHRNA4 CHRNA7 CHRNB2 COMT DRD2
2 personality disorder 29.6 CHRNA4 COMT DRD2 MAOA OPRM1 SLC6A3
3 lung cancer susceptibility 2 11.2
4 pycnodysostosis 10.4 CHRNA4 CHRNB2
5 familial hypocalciuric hypercalcemia 10.4 CHRNA4 CHRNB2
6 hyperekplexia 1 10.3 CHRNA3 CHRNA4 CHRNB2
7 galloway-mowat syndrome 10.3 CHRNA3 CHRNA5
8 pyromania 10.3 DRD2 MAOA SLC6A3
9 vascular skin disease 10.3 CHRNA3 CHRNA5 CHRNB3
10 c8 deficiency, type ii 10.3 COMT DRD2 OPRM1
11 apperceptive agnosia 10.3 ANKK1 COMT DRD2
12 cytomegalic congenital adrenal hypoplasia 10.3 COMT DRD2 MAOA
13 myopathy, distal, with early respiratory failure, autosomal dominant 10.3 COMT SLC6A3 TPH1
14 renpenning syndrome 10.3 COMT MAOA TPH1
15 colorectal adenocarcinoma 10.3 COMT DRD2 MAOA SLC6A3
16 multiple personality disorder 10.3 COMT MAOA TPH1
17 postencephalitic parkinson disease 10.3 DRD2 MAOA TPH1
18 cholesteatoma 10.3 COMT DRD2 SLC6A3
19 mucinous adenocarcinoma 10.3 DRD2 MAOA SLC6A3
20 testicular leydig cell tumor 10.3 COMT OPRM1 TPH1
21 hemochromatosis, type 2a 10.3 COMT DRD2 MAOA SLC6A3
22 keratosis 10.3 COMT MAOA TPH1
23 ovarian mucinous adenocarcinoma 10.3 GSTM1 GSTT1 SLC6A3
24 18p deletion syndrome 10.3 ANKK1 DRD2 OPRM1 SLC6A3
25 rhinoscleroma 10.2 COMT DRD2
26 hereditary multiple exostoses 10.2 COMT DRD2 MAOA
27 benign epilepsy with centrotemporal spikes 10.2 COMT DRD2 MAOA TPH1
28 parotid gland cancer 10.2 COMT DRD2 SLC6A3 TPH1
29 peripheral vertigo 10.2 COMT OPRM1
30 brain glioblastoma multiforme 10.2 COMT DRD2 SLC6A3 TPH1
31 hypoglycemia 10.2 ANKK1 DRD2 OPRM1
32 aortic valve disease 2 10.2 COMT DRD2 SLC6A3
33 carotid stenosis 10.2 COMT DRD2 MAOA SLC6A3 TPH1
34 hepatitis d 10.2 COMT DRD2 MAOA SLC6A3 TPH1
35 strongyloidiasis 10.2 ANKK1 COMT DRD2 MAOA SLC6A3
36 retinoblastoma 10.2 COMT DRD2 MAOA SLC6A3 TPH1
37 fechtner syndrome 10.2 COMT MAOA TPH1
38 chronic conjunctivitis 10.2 CHRNA7 COMT DRD2 SLC6A3 TPH1
39 paraphilia disorder 10.2 CHRNA7 COMT DRD2 MAOA SLC6A3
40 transmitted_by 10.2 CHRNA3 CHRNA5 CHRNB3 DRD2 OPRM1 SLC6A3
41 autism spectrum disorder 10.1 COMT OPRM1 SLC6A3
42 cecal benign neoplasm 10.1 ANKK1 COMT DRD2 MAOA SLC6A3 TPH1
43 cholestasis-lymphedema syndrome 10.1 COMT MAOA
44 ellis-van creveld syndrome 10.1 CHRNA4 CHRNA7 COMT DRD2 MAOA SLC6A3
45 hypereosinophilic syndrome 10.0 CHRNA3 CHRNA5 CHRNB4 DRD2 GSTM1 MAOA
46 lung cancer 10.0
47 preeclampsia/eclampsia 5 10.0 ANKK1 CHRNA6 COMT DRD2 MAOA OPRM1
48 alcohol dependence 10.0
49 anxiety disorder 9.9
50 pathological gambling 9.8

Graphical network of the top 20 diseases related to Nicotine Dependence, Protection Against:



Diseases related to Nicotine Dependence, Protection Against

Symptoms & Phenotypes for Nicotine Dependence, Protection Against

Symptoms by clinical synopsis from OMIM:

188890

Clinical features from OMIM:

188890

MGI Mouse Phenotypes related to Nicotine Dependence, Protection Against:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 CHRNB3 CHRNB4 COMT DRD2 GABBR2 MAOA
2 homeostasis/metabolism MP:0005376 9.97 DRD2 GABBR2 MAOA OPRM1 SLC6A3 TPH1
3 integument MP:0010771 9.56 CHRNA4 CHRNB2 CHRNB4 DRD2 GABBR2 OPRM1
4 nervous system MP:0003631 9.44 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Drugs & Therapeutics for Nicotine Dependence, Protection Against

Drugs for Nicotine Dependence, Protection Against (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 417)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
2
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
3
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
4
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
5
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
6
Guaifenesin Approved, Vet_approved Phase 4,Phase 1 93-14-1 3516
7
Methadone Approved Phase 4,Phase 2,Phase 1 76-99-3 4095
8
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
9
Carbon monoxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 630-08-0 281
10
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
11
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
12
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 52485-79-7 40400 644073
13
Montelukast Approved Phase 4,Phase 2 158966-92-8 5281040
14
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
15
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
16
Terbutaline Approved Phase 4 23031-25-6 5403
17
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 1 113-45-1 4158
18
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
19
Insulin Glargine Approved Phase 4 160337-95-1
20
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 1 57-83-0 5994
21
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
22
Procaterol Approved Phase 4 72332-33-3 688561
23
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
24
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
25
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
26
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
27
Norgestimate Approved Phase 4 35189-28-7 6540478
28
Eszopiclone Approved Phase 4 138729-47-2 969472
29
Sertraline Approved Phase 4 79617-96-2 68617
30 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 1
31 Antidotes Phase 4,Phase 2
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 4,Phase 2,Phase 1
35 Expectorants Phase 4,Phase 2
36 N-monoacetylcystine Phase 4,Phase 2
37 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Phase 2
47 Antitussive Agents Phase 4,Phase 1
48 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 1
50 Narcotics Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 1236)
id Name Status NCT ID Phase
1 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Unknown status NCT02252341 Phase 4
2 Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers Unknown status NCT01714323 Phase 4
3 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4
4 Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption Unknown status NCT01494246 Phase 4
5 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
6 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4
7 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4
8 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4
9 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence Completed NCT00178685 Phase 4
10 Tobacco Cessation in Postmenopausal Women (Part I) - 1 Completed NCT00061061 Phase 4
11 Chemical Dependency and Smoking Cessation: Patient's Views - 1 Completed NCT00051883 Phase 4
12 Bupropion and Weight Control for Smoking Cessation - 1 Completed NCT00006170 Phase 4
13 Bupropion as an Adjunct to the Nicotine Patch Plus CBT Completed NCT00142831 Phase 4
14 Bupropion for Smoking Cessation During Pregnancy Completed NCT01390246 Phase 4
15 Helping Hospitalized Patients Quit Smoking Completed NCT01575145 Phase 4
16 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts Completed NCT01023659 Phase 4
17 Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke Completed NCT00307203 Phase 4
18 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
19 Neuropsychological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
20 Smoking Cessation Intervention: Effectiveness in Primary Care Completed NCT00296647 Phase 4
21 Bupropion Alone or Combined With Nicotine Gum Completed NCT01621022 Phase 4
22 Evaluation of Treatments to Improve Smoking Cessation Medication Adherence Completed NCT01120704 Phase 4
23 Identifying Treatments to Motivate Smokers to Quit Completed NCT01122238 Phase 4
24 Bupropion SR Plus Counseling for Smoking Cessation Completed NCT01621009 Phase 4
25 Identifying Optimal Smoking Cessation Intervention Components (Cessation) Completed NCT01116986 Phase 4
26 Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment Completed NCT00749463 Phase 4
27 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms Completed NCT00332644 Phase 4
28 Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources Completed NCT01342523 Phase 4
29 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers Completed NCT01048944 Phase 4
30 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4
31 Measuring Smoking Behaviors While Using Varenicline Completed NCT00948155 Phase 4
32 Effects of Chantix on Relapse Prevention for Smoking Cessation Completed NCT00948649 Phase 4
33 Comparison of Internet Stop Smoking Intervention to Usual Care on Smoking Cessation at 6 Months Completed NCT01639079 Phase 4
34 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4
35 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4
36 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4
37 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4
38 Varenicline Effects In Schizophrenic Smokers Completed NCT00548470 Phase 4
39 Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch) Completed NCT00000447 Phase 4
40 STOP Study: Effectiveness of Zyban in a Clinical Population Completed NCT01015170 Phase 4
41 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4
42 Three Year Follow up of a Randomised Controlled Trial (RCT) of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness Completed NCT00350493 Phase 4
43 Treatment of Nicotine Dependence and Acute Depression Completed NCT00186446 Phase 4
44 Smoking Cessation in Hospitalized Smokers Completed NCT01289275 Phase 4
45 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
46 Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease Completed NCT00181818 Phase 4
47 Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State Completed NCT02103374 Phase 4
48 Impact of Smoking Cessation on Sleep - 5 Completed NCT00132821 Phase 4
49 Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta Completed NCT00181792 Phase 4
50 Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) Completed NCT02473237 Phase 4

Search NIH Clinical Center for Nicotine Dependence, Protection Against

Cochrane evidence based reviews: tobacco use disorder

Genetic Tests for Nicotine Dependence, Protection Against

Genetic tests related to Nicotine Dependence, Protection Against:

id Genetic test Affiliating Genes
1 Tobacco Addiction, Susceptibility to 29
2 Tobacco Use Disorder 29
3 Nicotine Dependence 29

Anatomical Context for Nicotine Dependence, Protection Against

Publications for Nicotine Dependence, Protection Against

Variations for Nicotine Dependence, Protection Against

ClinVar genetic disease variations for Nicotine Dependence, Protection Against:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GABBR2 GABABR2, HAPLOTYPE, TATA (rs1435252, rs3780422, rs2779562, rs3750344) undetermined variant risk factor

Copy number variations for Nicotine Dependence, Protection Against from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256991 9 99300000 102600000 Gain or loss GPR51 Nicotine dependence

Expression for Nicotine Dependence, Protection Against

Search GEO for disease gene expression data for Nicotine Dependence, Protection Against.

Pathways for Nicotine Dependence, Protection Against

Pathways related to Nicotine Dependence, Protection Against according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
2
Show member pathways
13.14 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3
Show member pathways
13.07 AKR1B10 COMT CYP2A6 GSTM1 GSTT1 MAOA
4
Show member pathways
12.59 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
5
Show member pathways
12.52 CHRNA3 CHRNA4 CHRNA6 CHRNA7 CHRNB2 CHRNB4
6
Show member pathways
12.49 CHRNA7 CYP2A6 GSTM1 GSTT1 MAOA
7 12.4 COMT GABBR2 OPRM1 TPH1
8 12.01 CHRNA4 CHRNA7 CHRNB2 CHRNB4 MAOA TPH1
9
Show member pathways
11.82 DRD2 MAOA SLC6A3
10
Show member pathways
11.74 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNB2 DRD2
11
Show member pathways
11.62 CYP2A6 GSTM1 GSTT1
12 11.27 CHRNA4 CHRNA6 CHRNA7 CHRNB2
13
Show member pathways
11.15 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
14
Show member pathways
11.08 COMT MAOA SLC6A3
15 11.01 CYP2A6 GSTM1 GSTT1
16
Show member pathways
10.95 COMT MAOA TPH1
17 10.71 COMT MAOA
18
Show member pathways
10.7 COMT MAOA
19
Show member pathways
10.58 AKR1B10 CYP2A6
20
Show member pathways
10.43 CHRNA3 CHRNB4

GO Terms for Nicotine Dependence, Protection Against

Cellular components related to Nicotine Dependence, Protection Against according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.91 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
2 dendrite GO:0030425 9.83 CHRNA3 CHRNA4 COMT DRD2 OPRM1
3 synapse GO:0045202 9.81 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
4 neuron projection GO:0043005 9.8 CHRNB3 CHRNB4 GABBR2 OPRM1 SLC6A3 TPH1
5 axon GO:0030424 9.78 COMT DRD2 OPRM1 SLC6A3
6 postsynaptic membrane GO:0045211 9.65 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
7 plasma membrane raft GO:0044853 9.54 CHRNA3 CHRNA7 CHRNB2
8 acetylcholine-gated channel complex GO:0005892 9.23 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
9 integral component of membrane GO:0016021 10.28 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
10 plasma membrane GO:0005886 10.27 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Biological processes related to Nicotine Dependence, Protection Against according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.99 CHRNA4 CHRNA5 CHRNA6 GABBR2 OPRM1
2 response to hypoxia GO:0001666 9.93 CHRNA4 CHRNA7 CHRNB2 DRD2
3 cation transmembrane transport GO:0098655 9.93 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3 CHRNB4
4 response to ethanol GO:0045471 9.91 CHRNB2 DRD2 OPRM1 SLC6A3
5 locomotory behavior GO:0007626 9.91 CHRNA3 CHRNA4 CHRNB2 CHRNB4 DRD2 OPRM1
6 regulation of membrane potential GO:0042391 9.88 CHRNA3 CHRNA4 CHRNB2 CHRNB4
7 response to cocaine GO:0042220 9.85 CHRNB2 DRD2 OPRM1 SLC6A3
8 regulation of dopamine secretion GO:0014059 9.83 CHRNA4 CHRNA6 CHRNB2 DRD2
9 neuromuscular synaptic transmission GO:0007274 9.83 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3
10 protein heterooligomerization GO:0051291 9.82 CHRNB2 CHRNB3 CHRNB4
11 sensory perception of pain GO:0019233 9.81 CHRNA4 CHRNB2 OPRM1
12 regulation of postsynaptic membrane potential GO:0060078 9.8 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2 CHRNB3
13 cognition GO:0050890 9.79 CHRNA4 CHRNA7 CHRNB2
14 negative regulation of adenylate cyclase activity GO:0007194 9.78 DRD2 GABBR2 OPRM1
15 membrane depolarization GO:0051899 9.77 CHRNA4 CHRNA6 CHRNB2
16 action potential GO:0001508 9.75 CHRNA4 CHRNB2 CHRNB4
17 dopamine catabolic process GO:0042420 9.73 COMT MAOA SLC6A3
18 behavioral response to nicotine GO:0035095 9.72 CHRNA3 CHRNA4 CHRNA5 CHRNB2 CHRNB4
19 acetylcholine receptor signaling pathway GO:0095500 9.71 CHRNA3 CHRNA4 CHRNA7 CHRNB2
20 synaptic transmission, cholinergic GO:0007271 9.7 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3
21 smooth muscle contraction GO:0006939 9.69 CHRNB2 CHRNB4
22 response to acetylcholine GO:1905144 9.69 CHRNA3 CHRNA7 CHRNB2
23 regulation of dendrite morphogenesis GO:0048814 9.68 CHRNA3 CHRNB2
24 response to iron ion GO:0010039 9.68 DRD2 SLC6A3
25 regulation of smooth muscle contraction GO:0006940 9.68 CHRNA3 CHRNB4
26 behavioral response to ethanol GO:0048149 9.68 DRD2 OPRM1
27 positive regulation of long-term synaptic potentiation GO:1900273 9.67 CHRNA7 DRD2
28 dopamine metabolic process GO:0042417 9.67 COMT DRD2
29 prepulse inhibition GO:0060134 9.67 DRD2 SLC6A3
30 synaptic transmission involved in micturition GO:0060084 9.67 CHRNA3 CHRNB2 CHRNB4
31 neurological system process GO:0050877 9.66 CHRNA4 CHRNB2
32 neurotransmitter catabolic process GO:0042135 9.66 COMT MAOA
33 short-term memory GO:0007614 9.65 CHRNA7 COMT
34 catecholamine metabolic process GO:0006584 9.65 COMT MAOA
35 regulation of dopamine metabolic process GO:0042053 9.65 CHRNB2 SLC6A3
36 adenohypophysis development GO:0021984 9.64 DRD2 SLC6A3
37 response to nicotine GO:0035094 9.61 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2 CHRNB3
38 excitatory postsynaptic potential GO:0060079 9.28 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
39 signal transduction GO:0007165 10.31 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
40 transport GO:0006810 10.28 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
41 ion transport GO:0006811 10.14 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
42 ion transmembrane transport GO:0034220 10.02 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Molecular functions related to Nicotine Dependence, Protection Against according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 acetylcholine binding GO:0042166 9.92 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
2 extracellular ligand-gated ion channel activity GO:0005230 9.86 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3 ion channel activity GO:0005216 9.8 CHRNA3 CHRNA4 CHRNA7 CHRNB2 CHRNB4
4 drug binding GO:0008144 9.77 CHRNB2 CHRNB3 CHRNB4 DRD2 SLC6A3
5 ligand-gated ion channel activity GO:0015276 9.76 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.56 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
7 dopamine binding GO:0035240 9.43 DRD2 SLC6A3
8 acetylcholine receptor activity GO:0015464 9.17 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Sources for Nicotine Dependence, Protection Against

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....